BioCentury
ARTICLE | Company News

FDA approves Tecentriq in second-line NSCLC

October 18, 2016 7:00 AM UTC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said FDA approved PD-L1 inhibitor Tecentriq atezolizumab to treat non-small cell lung cancer in patients whose disease has progressed following platinum-containing chemotherapy, and with disease progression following treatment with a targeted therapy if their tumors have EGFR or anaplastic lymphoma kinase (ALK) mutations.

In September, Genentech said Tecentriq met the co-primary endpoints of the Phase III OAK study to treat NSCLC (see BioCentury Extra, Sept. 1). ...